|
We asked 40 pharma leaders, Into which pharmerging market — aside from China and India — is your company most interested in expanding?
| Brazil |
37% |
| Turkey |
5% |
| Russia |
26% |
| Indonesia |
5% |
| Argentina |
5% |
| South Africa |
5% |
| Other |
17% |
 |
|
|
|
|
|
|
|
21 August, 2012
|
| In this Issue |
Unanswered Questions in the UK Pricing Debate
When it comes to pharmaceutical pricing, the UK has always set the precedent. So the current debate over a proposed new system of value based pricing (VBP) to replace the PPRS has attracted an audience well beyond the country's own borders. But many questions about the reform remain unanswered, writes Leela Barham. Read more... |
Making the Case for Data Exclusivity
Data exclusivity has been criticized as governments experience the disconnect between a demographic of soaring healthcare costs, and a fiscal and debt crisis. So how do we build a constructive case against criticism and maintain the relevance of data exclusivity as an essential driver of new drug innovation? Carol Ann Williams reports. More... |
Elan to Spin Off Discovery Sciences
Elan Corporation has announced plans to spin off its discovery unit and Neotope Biosciences division to create an independent entity focused on R&D. Amy Ritter reports. More... |
UK Invests in $12.5 Million Stem Cell Institute
The UK is to invest £8 million ($12.5 million) in a new center that will be dedicated to stem-cell biology and medicine, with the aim of developing new therapeutic approaches to illnesses that currently have no effective treatments. More...
|
|
|
|
